$OCS News

JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $23

Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating

Baird Maintains Outperform on Oculis Holding, Lowers Price Target to $38

Stifel Maintains Buy on Oculis Holding, Lowers Price Target to $40

Why Is Oculis Stock Sinking Monday?

Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $45

Needham Maintains Buy on Oculis Holding, Lowers Price Target to $38

HC Wainwright & Co. Maintains Buy on Oculis Holding, Lowers Price Target to $26

Oculis Holding Reports Topline Results From Phase 3 DIAMOND-1 And DIAMOND-2 Trials Of OCS-01 Eye Drops In Patients With DME; Primary BCVA Endpoint Not Met

Guggenheim Initiates Coverage On Oculis Holding with Buy Rating, Announces Price Target of $75

JP Morgan Maintains Overweight on Oculis Holding, Raises Price Target to $42

Needham Maintains Buy on Oculis Holding, Raises Price Target to $46

HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $47

Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts

Oculis Holding Q1 EPS $(0.63) Misses $(0.49) Estimate, Sales $266.845K Miss $320.000K Estimate

HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $44 Price Target

Oculis Completes Final Patient Visits In Both Phase 3 DIAMOND Trials For OCS-01 Diabetic Macular Edema Eye Drop Treatment

Oculis Receives European Medicines Agency PRIME Designation For Privosegtor In Optic Neuritis, Accelerating PIONEER Registrational Program Across Three Global Trials

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Oculis Holding (NasdaqGM:OCS) Valuation Check After Strong Three Year Gains And Recent Share Price Pullback